Dr. Yuelie Lu joined Turning Point Therapeutics in July 2018 as vice president of CMC operations, overseeing process development and manufacturing of drug substance and drug product, as well as analytical development and regulatory CMC for clinical trial material supplies. Dr. Lu has worked in various leadership roles in his 25 years in the pharmaceutical and biotech industry including Schering-Plough (now Merck), Amgen, Lexicon Pharmaceuticals, Pharmacyclics (now part of AbbVie) and Portola Pharmaceuticals. Prior to joining Turning Point, he led teams through the successful launch and commercialization of breakthrough therapy ibrutinib (Imbruvica®), a Bruton’s tyrosine kinase (BTK) inhibitor. At Portola, he worked on betrixaban (Bevyxa®), a Factor Xa inhibitor, which gained FDA fast-track designation. Dr. Lu also has extensive process development experience for many Phase 1-3 small molecules including Portola’s cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers, Lexicon’s telotristat etiprate for carcinoid syndrome, sotagliflozin for Type I/II diabetes and Amgen’s motesanib diphosphate for cancer. Dr. Lu received his Ph.D. in organic chemistry from Purdue University, a Master of Science degree in polymer chemistry and a Bachelor of Science degree in chemistry from the University of Science and Technology of China.